New drug combo tested for tough breast cancer
NCT ID NCT05631795
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety of combining two drugs, alpelisib and fulvestrant, in 40 men and post-menopausal women with a certain type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that had worsened after hormone therapy. The goal was to track side effects. The study is complete, providing safety data for this combination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
alpelisib and fulvestrant
What this could lead to
If successful, this could confirm a safe treatment option for people with a specific type of advanced breast cancer that has stopped responding to hormone therapy.
What could go wrong
This is a small, completed safety study in India, not designed to prove effectiveness. Side effects like high blood sugar and liver issues are known risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Guwahati, Assam, 781016, India
-
Novartis Investigative Site
Surat, Gujarat, 395009, India
-
Novartis Investigative Site
Thalassery, Kerala, 670103, India
-
Novartis Investigative Site
Trivandrum, Kerala, 695 011, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 440001, India
-
Novartis Investigative Site
Pune, Maharashtra, 411040, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110029, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500004, India
-
Novartis Investigative Site
Ahmedabad, 380016, India
-
Novartis Investigative Site
Kolkata, 700026, India